Abstract:Abstract Breast cancer is the most diagnosed cancer in the U.S., with a 5-year survival rate of less than 30% for patients with distant metastases. Bone metastases are present in over 70% of metastatic breast cancer patients, and current treatments treat the symptoms of osteolytic bone metastasis (OBM), but do not improve survival rates. OBM is characterized by an increase in osteoclast proliferation and bone-resorbing activity. Moreover, receptor tyrosine kinase, Ephrin-type-A 2 receptor (EphA2), is highly expressed in bone metastases, and previous evidence suggests its involvement in OBM and anti-tumor immunity. EphA2 participates in both forward and reverse signaling during receptor/ligand engagement and mediates various biological processes such as tissue organization and homeostasis and inflammation, as well as oncogenic processes like epithelial-mesenchymal transition. However, the mechanism by which EphA2 mediates the expansion of osteoclasts is not well understood. Analysis of transcriptomic data of patients with bone metastases in The Metastatic Breast Cancer Project (Provisional, December 2021) resulted in over 3500 genes that significantly correlated with EphA2 expression (Spearman's Correlation ≥ 0.35). Using a publicly available Gene Ontology reference list for myeloid differentiation, we identified 155 genes that have a significant positive correlation with EphA2 expression. To assess the effect of EphA2 expression on genes associated with osteoclasts, we compared the same samples to reference lists for osteoclast differentiation and proliferation. We identified 17 genes of interest that significantly correlate with EphA2 expression, further underscoring the possible involvement of EphA2 in OBM. We then compared the patients without bone metastases to the same osteoclast reference lists and found no significant correlations. We hypothesize that increased expression of EphA2 in breast cancer cells at the site of bone metastasis promotes osteoclast expansion, leading to OBM. We aim to investigate EphA2 reverse signaling in myeloid progenitor cells, osteoclasts, and bone metastasis-associated macrophages. We will utilize breast cancer mouse models to elucidate the effects of EphA2 inhibition on immune cell populations, bone metastasis, and tumor progression. We aim to reduce OBM and tumor burden by reducing the expansion of osteoclasts and shifting the immune cells to an anti-tumorigenic phenotype, which will offer new treatment strategies for osteolytic breast cancer. Citation Format: Dominique Parker, Verra Ngwa, Logan Northcutt, Natalie Bennett, Erik Beadle, Jade Miller, JIn Chen, Julie Rhoades. EphA2 Expression in Breast Cancer Mediates Osteoclast Expansion and Promotes Osteolytic Bone Metastasis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 1324.

Overexpression of a functional calcium-sensing receptor dramatically increases osteolytic potential of MDA-MB-231 cells in a mouse model of bone metastasis through epiregulin-mediated osteoprotegerin downregulation

In Vitro and in Vivo Killing Effects of Methionine Enkephalin on Osteosarcoma.

Estrogen receptor β exhibited anti-tumor effects on osteosarcoma cells by regulating integrin, IAP, NF-kB/BCL-2 and PI3K/Akt signal pathway.

Association of EP2 Receptor and SLC19A3 in Regulating Breast Cancer Metastasis.

Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Caveolin-1 Down-Regulation Activates Estrogen Receptor Alpha Expression and Leads to 17 Beta-Estradiol-Stimulated Mammary Tumorigenesis

The CaSR in Pathogenesis of Breast Cancer: A New Target for Early Stage Bone Metastases

RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model

P2RX7 inhibition reduces breast cancer induced osteolytic lesions - implications for bone metastasis

Effects of calcitonin gene-related peptide on osteoprotegerin and RANKL expressions in osteoblast cells in bone metastasis microenvironment of breast cancer in vitro

Expression Profile of Receptor Activator of Nuclear-Κb (RANK), RANK Ligand (RANKL) and Osteoprotegerin (OPG) in Breast Cancer.

Exosomal miR-19a and IBSP cooperate to induce osteolytic bone metastasis of estrogen receptor-positive breast cancer

Tumor-derived platelet-derived growth factor-BB plays a critical role in osteosclerotic bone metastasis in an animal model of human breast cancer

Breast cancer exosomes contribute to pre-metastatic niche formation and promote bone metastasis of tumor cells

Eribulin mesylate induces bone mass loss by promoting osteoclastic bone resorption in mice

Calcium-sensing Receptor, a Potential Biomarker Revealed by Large-scale Public Databases and Experimental Verification in Metastatic Breast Cancer

Endogenous osteoprotegerin (OPG) represses ERα and promotes stemness and chemoresistance in breast cancer cells

RAS‑stimulated release of exosomal miR‑494‑3p promotes the osteolytic bone metastasis of breast cancer cells

Osteoblasts are “educated” by crosstalk with metastatic breast cancer cells in the bone tumor microenvironment

Breast cancer cell‐derived exosomal miR‐20a‐5p promotes the proliferation and differentiation of osteoclasts by targeting SRCIN1

Abstract 1324: EphA2 Expression in Breast Cancer Mediates Osteoclast Expansion and Promotes Osteolytic Bone Metastasis